Cited by 22Systemic Lupus Erythematosus ResearchVasculitis and related conditionsBlood Coagulation and Thrombosis Mechanisms

Antiphospholipid syndrome: an update for clinicians and scientists

Open access
Vreede, Andrew P., Bockenstedt, Paula L., Knight, Jason S.·2017·Current Opinion in Rheumatology

Abstract

Purpose of review: Antiphospholipid syndrome (APS) is a leading acquired cause of thrombosis and pregnancy loss. Upon diagnosis (which is unlikely to be made until at least one morbid event has occurred), anticoagulant medications are typically prescribed in an attempt to prevent future events. This approach is not uniformly effective and does not prevent associated autoimmune and inflammatory complications. The goal of this review is to update clinicians and scientists on mechanistic and clinically relevant studies from the past 18 months, which have especially focused on inflammatory aspects of APS pathophysiology. Recent findings: How antiphospholipid antibodies leverage receptors and signaling pathways to activate cells is being increasingly defined. Although established mediators of disease pathogenesis (like endothelial cells and the complement system) continue to receive intensive study, emerging concepts (such as the role of neutrophils) are also receiving increasing attention. In-vivo animal studies and small clinical trials are demonstrating how repurposed medications (hydroxychloroquine, statins, and rivaroxaban) may have clinical benefit in APS, with these concepts importantly supported by mechanistic data. Summary: As anticoagulant medications are not uniformly effective and do not comprehensively target the underlying pathophysiology of APS, there is a continued need to reveal the inflammatory aspects of APS, which may be modulated by novel and repurposed therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/bor.0000000000000410

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • aCL antibody titres in APS and SLE are associated with thrombosis and pregnancy complications.

    “aCL antibody titres in these diseases are associated with thrombosis and pregnancy complications253.”

    From The role of mitochondria in rheumatic diseases (2022) · cites this paper as [253]

    The Introduction (page not available) links antiphospholipid antibodies in lupus and APS to thrombotic and obstetric complications, and identifies anticardiolipin positivity in patients with recurrent thrombosis. It does not establish that anticardiolipin antibody titres, specifically, are associated with both thrombosis and pregnancy complications. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Vreede, A. P., Bockenstedt, P. L., & Knight, J. S.
Affiliations
  • Division of Rheumatology
  • University of Michigan (US)
Corresponding author
Knight, Jason S.
Venue
Current Opinion in Rheumatology
Published
2017-09
Volume
29
Issue
5
Pages
458-466
ISSN
  • 1040-8711 (ISSN-L)
  • 1531-6963
OpenAlex
W2617016771
Cited by
22
References
77
Citations by year
2025: 1 · 2024: 2 · 2023: 2 · 2022: 6 · 2021: 4 · 2020: 2 · 2019: 4 · 2018: 1
FWCI
0.31
Type
journal article
Language
en
Open access
Locations
  • Current Opinion in Rheumatology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Arthritis and Musculoskeletal and Skin Diseases (K08AR066569)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vasculitis and related conditions
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
antiphospholipid syndrome, antiphospholipid antibodies, thrombosis, miscarriage, inflammation, neutrophils, endothelial cells, complement system, hydroxychloroquine, statins, rivaroxaban, drug repurposing, anticoagulation, autoimmune complications
MeSH terms
Anticoagulants, Humans, Thrombosis, Global Health, Incidence, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review